At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
dalteparindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN(REGISTERED) (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES
In Brief
A Phase 2 clinical trial evaluating dalteparin for Venous Thromboembolism. Completed, enrolled 38 participants across 26 sites in 5 countries.
Detailed Summary
Three month treatment of acute VTE with Fragmin in pediatric cancer patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVenous Thromboembolism
CountriesNorway, Russia, Slovenia, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2009
First PostedAug 2009
Primary CompletionMar 2018
TodayJul 2026
First PostedAug 6, 2009
Enrollment StartAug 1, 2009
Primary CompletionMar 1, 2018
TodayJul 2, 2026
Enrollment to primary: 8.6 yearsPosted 16.9 years ago
Interventions
dalteparindrug
dalteparin subcutaneous injection